A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

abstract

  • This drug combination showed no significant clinical response and was associated with reproducible toxicity. The predominance of myalgia in the absence of elevated serum cytokines suggests a non-inflammatory etiology of this toxicity.

publication date

  • February 2003

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0169-5002(02)00447-6

PubMed ID

  • 12581572

Additional Document Info

start page

  • 191

end page

  • 6

volume

  • 39

number

  • 2